Veru Inc logo

VERU

Veru Inc

$20.39

Earnings Summary

Revenue
$13.03Mn
Net Profits
$-14.18Mn
Net Profit Margins
-108.82%

Highlights

Revenue:

Veru Inc’s revenue fell -2.34% since last year same period to $13.03Mn in the Q1 2022. On a quarterly growth basis, Veru Inc has generated -7.83% fall in its revenue since last 3-months.

Net Profits:

Veru Inc’s net profit fell -398.17% since last year same period to $-14.18Mn in the Q1 2022. On a quarterly growth basis, Veru Inc has generated -122.22% fall in its net profits since last 3-months.

Net Profit Margins:

Veru Inc’s net profit margin fell -410.1% since last year same period to -108.82% in the Q1 2022. On a quarterly growth basis, Veru Inc has generated -141.1% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Veru Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.16
EPS Estimate Current Year
-0.16

Highlights

EPS Estimate Current Quarter:

Veru Inc’s earning per share (EPS) estimates for the current quarter stand at -0.16 - a -6.67% fall from last quarter’s estimates.

EPS Estimate Current Year:

Veru Inc’s earning per share (EPS) estimates for the current year stand at -0.16.

Key Ratios

Key ratios of the Veru Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.18
Return on Assets (ROA)
-0.06
Return on Equity (ROE)
-0.16
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Veru Inc’s earning per share (EPS) fell -350% since last year same period to -0.18 in the Q1 2022. This indicates that the Veru Inc has generated -350% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Veru Inc’s return on assets (ROA) stands at -0.06.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Veru Inc’s return on equity (ROE) stands at -0.16.

Dividend Per Share (DPS):

Veru Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.15
-0.18
-20%

Company Information

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer. VERU-100 is a novel, proprietary peptide formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor agonist that targets and activates the androgen receptor in AR+/ER+/HER2- metastatic breast cancer without unwanted masculinizing side effects. VERU-111 is also being advanced into a Phase 3 trial for the treatment of hospitalized patients with COVID-19 who are at high risk for acute respiratory distress syndrome.

Organisation
Veru Inc
Headquarters
Miami, Florida, United States
Employees
339
Industry
Consumer Non-Durables
CEO
Mitchell Steiner